Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) saw a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 3,236,659 shares, a drop of 46.9% from the October 15th total of 6,094,189 shares. Based on an average daily volume of 1,127,185 shares, the short-interest ratio is presently 2.9 days. Approximately 5.9% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
TARA has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.25.
Get Our Latest Analysis on TARA
Protara Therapeutics Stock Down 4.0%
Shares of TARA stock traded down $0.10 during trading hours on Tuesday, reaching $2.29. 176,275 shares of the company’s stock were exchanged, compared to its average volume of 881,761. Protara Therapeutics has a fifty-two week low of $2.09 and a fifty-two week high of $7.82. The stock has a market capitalization of $140.69 million, a P/E ratio of -1.65 and a beta of 1.54. The business has a fifty day moving average price of $2.86 and a 200-day moving average price of $4.37.
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.02. As a group, research analysts expect that Protara Therapeutics will post -1.37 EPS for the current fiscal year.
Institutional Trading of Protara Therapeutics
A number of hedge funds have recently bought and sold shares of TARA. Baker BROS. Advisors LP raised its position in shares of Protara Therapeutics by 89.8% during the third quarter. Baker BROS. Advisors LP now owns 1,843,795 shares of the company’s stock valued at $5,624,000 after buying an additional 872,181 shares during the last quarter. Marshall Wace LLP grew its position in Protara Therapeutics by 120.1% during the third quarter. Marshall Wace LLP now owns 1,543,284 shares of the company’s stock worth $4,707,000 after buying an additional 842,263 shares in the last quarter. Empowered Funds LLC bought a new position in Protara Therapeutics during the third quarter valued at about $191,000. Fisher Asset Management LLC increased its stake in Protara Therapeutics by 30.2% during the third quarter. Fisher Asset Management LLC now owns 129,612 shares of the company’s stock valued at $395,000 after acquiring an additional 30,046 shares during the period. Finally, Alps Advisors Inc. increased its stake in Protara Therapeutics by 36.3% during the third quarter. Alps Advisors Inc. now owns 77,735 shares of the company’s stock valued at $237,000 after acquiring an additional 20,694 shares during the period. 38.13% of the stock is owned by institutional investors.
Protara Therapeutics Company Profile
Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.
See Also
- Five stocks we like better than Protara Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
